Can You Take Evenity (Romosozumab) with Opioids Like Oxycodone, Hydrocodone, or Tramadol?

Why This Combination Comes Up in Clinical Practice

Patients prescribed romosozumab for severe osteoporosis frequently have concurrent pain conditions. Vertebral compression fractures, degenerative joint disease, and post-surgical pain commonly lead to opioid prescriptions in this same demographic. The FRAME trial (N=7,180) enrolled postmenopausal women with a mean age of 70.9 years, a population where chronic pain prevalence exceeds 50% according to CDC estimates.

The overlap is not trivial. Among Medicare beneficiaries with osteoporosis, approximately 30% received at least one opioid prescription within a 12-month period according to a 2019 analysis published in the Journal of Bone and Mineral Research. This means clinicians routinely face the question of whether romosozumab and opioids can coexist safely in a treatment regimen.

Romosozumab's FDA-approved prescribing information lists no specific drug-drug interactions. The label states that "no formal drug interaction studies have been conducted with romosozumab." This absence of data reflects the drug's mechanism of clearance rather than an oversight. It requires clinical reasoning to fill the gap.

Pharmacokinetic Profile: No Overlapping Metabolic Pathways

Romosozumab is a humanized IgG2 monoclonal antibody that inhibits sclerostin. Like all therapeutic monoclonal antibodies, it undergoes proteolytic degradation into small peptides and amino acids through the reticuloendothelial system. It does not interact with cytochrome P450 enzymes, UDP-glucuronosyltransferases, or drug transporters such as P-glycoprotein (P-gp) [1].

Opioids, by contrast, are small-molecule drugs with well-characterized hepatic metabolism:

Oxycodone is primarily metabolized by CYP3A4 to noroxycodone (a weaker metabolite) and by CYP2D6 to oxymorphone (a more potent metabolite). Strong CYP3A4 inhibitors like ketoconazole increase oxycodone AUC by approximately 2- to 3-fold according to the oxycodone FDA label [2].

Hydrocodone follows a parallel pattern. CYP2D6 converts it to hydromorphone, while CYP3A4 produces norhydrocodone. CYP2D6 poor metabolizers generate less hydromorphone and may experience reduced analgesic effect [3].

Tramadol depends heavily on CYP2D6 for conversion to its active metabolite O-desmethyltramadol (M1), which has 200-fold greater affinity for the mu-opioid receptor than the parent compound. CYP3A4 produces the inactive N-desmethyl metabolite. The tramadol FDA label warns that CYP2D6 ultra-rapid metabolizers face heightened respiratory depression risk [4].

Because romosozumab never enters the CYP system, it cannot inhibit, induce, or compete with any of these pathways. No dose adjustment of either drug class is required on pharmacokinetic grounds alone.

Pharmacodynamic Concerns: Fall Risk Is the Real Issue

The absence of a metabolic interaction does not mean the combination is risk-free. Both drug classes contribute to fall risk through distinct mechanisms, and falls represent the proximate cause of most osteoporotic fractures.

Opioids cause dose-dependent sedation, dizziness, and impaired psychomotor function. A meta-analysis in the British Medical Journal (2015) found that opioid use in adults over 65 was associated with an adjusted odds ratio of 1.60 (95% CI 1.35-1.90) for falls requiring medical attention [5]. The risk was highest in the first two weeks of a new prescription or dose increase.

Romosozumab itself does not cause sedation. In the FRAME trial, dizziness rates were similar between romosozumab (2.0%) and placebo (1.7%) groups [6]. The pharmacodynamic concern is indirect: patients on romosozumab have severe osteoporosis by definition (the FDA indication requires high fracture risk), so any fall carries disproportionate consequences. A patient whose T-score is -3.5 and who is sedated by hydrocodone faces a compounded fracture probability that neither drug's label individually captures.

Tramadol Deserves Special Attention

Tramadol occupies a unique position among opioids relevant to osteoporosis patients. Beyond its opioid agonist activity, tramadol inhibits serotonin and norepinephrine reuptake, creating pharmacological effects that do not apply to oxycodone or hydrocodone.

Three specific concerns merit discussion:

Seizure threshold reduction. Tramadol lowers the seizure threshold in a dose-dependent manner. The FDA label reports seizures in 0.1-0.8% of patients. Seizure-related falls in an osteoporotic patient can produce catastrophic fractures [4].

Bone metabolism effects. Preclinical data suggest serotonin modulates osteoblast and osteoclast activity. A study published in Bone (2012) demonstrated that gut-derived serotonin inhibits osteoblast proliferation [7]. Whether tramadol's serotonergic activity meaningfully opposes romosozumab's anabolic bone effects in humans remains unproven, but the theoretical concern exists.

Hyponatremia. Both tramadol (via SIADH) and osteoporosis treatments in elderly patients carry hyponatremia risk. Hyponatremia itself is an independent risk factor for osteoporotic fractures, with a 2010 meta-analysis in the Journal of Clinical Endocrinology & Metabolism reporting an odds ratio of 2.25 for fracture in hyponatremic patients [8].

For these reasons, if opioid analgesia is required in a romosozumab-treated patient, oxycodone or hydrocodone may be preferable to tramadol from a bone-health standpoint, though the evidence base for this preference is indirect.

The Cardiovascular Intersection

Romosozumab carries an FDA boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death. This warning emerged from the ARCH trial (N=4,093), which compared romosozumab to alendronate and found a 2.0% vs. 1.1% rate of adjudicated major adverse cardiovascular events over the first 12 months [9].

Opioids carry their own cardiovascular considerations. Chronic opioid use has been associated with QTc prolongation (particularly methadone, but also tramadol at high doses) and with increased cardiovascular mortality in observational studies. A 2012 JAMA Internal Medicine study found a dose-dependent increase in cardiovascular risk with chronic opioid therapy (HR 1.77 for high-dose opioids, 95% CI 1.44-2.17) [10].

While no study has examined the combined cardiovascular impact of romosozumab plus opioids, the prescribing clinician should document baseline cardiovascular risk before initiating romosozumab in any patient already receiving chronic opioid therapy. The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend against romosozumab in patients who have had a myocardial infarction or stroke within the preceding year [11].

Monitoring Recommendations for Concurrent Use

No DDI database (Lexicomp, Micromedex, Clinical Pharmacology) flags a direct interaction between romosozumab and any opioid as of May 2026. Standard monitoring applies to each drug independently, but the combination warrants heightened attention in specific domains.

Fall-risk assessment. Use a validated tool (Timed Up and Go, or the CDC STEADI algorithm) at each romosozumab injection visit (monthly for 12 months). Reassess after any opioid dose change [12]. The CDC STEADI toolkit provides freely available screening instruments.

Cardiovascular screening. Obtain baseline blood pressure, lipid panel, and cardiovascular history before romosozumab initiation. Repeat assessment at 6 months. If the patient is on chronic opioids, consider an ECG to evaluate QTc, particularly if tramadol is the agent [9].

Bone turnover markers. Measure serum P1NP (procollagen type 1 N-terminal propeptide) and CTX (C-terminal telopeptide) at baseline and at 3, 6, and 12 months. A blunted P1NP response (failure to increase by at least 100% from baseline by month 1) may signal suboptimal romosozumab efficacy and warrants investigation of contributing factors, including concurrent medications [6].

Calcium and vitamin D. The romosozumab label requires correction of hypocalcemia before treatment. Opioid-related constipation may reduce calcium absorption from supplements. Counsel patients on adequate hydration and consider divided calcium dosing (500 mg twice daily rather than 1 to 000 mg once daily) to optimize absorption [1].

Pain management review. Reassess the opioid indication at each visit. If the opioid was prescribed for an osteoporotic fracture, romosozumab's bone-building effect may reduce pain over time. The FRAME trial showed a 73% reduction in new vertebral fractures at 12 months (0.5% romosozumab vs. 1.8% placebo, p<0.001), which may decrease the ongoing need for opioid analgesia [6].

Patient Counseling Points

Patients receiving both medications need specific, actionable guidance. The following counseling points address the most common clinical scenarios.

Tell patients to report new or worsening dizziness, drowsiness, or unsteadiness to their prescriber promptly. These symptoms may indicate opioid dose excess in the context of age-related pharmacokinetic changes (reduced renal clearance, decreased hepatic blood flow) rather than a drug interaction with romosozumab.

Advise patients not to drive or operate heavy machinery during opioid dose titration, and to use assistive devices (cane, walker, grab bars) proactively during this period. A single fall in a patient with a T-score below -2.5 carries a vertebral fracture probability exceeding 20% depending on FRAX score and fall mechanics.

Remind patients that romosozumab is a 12-month treatment. The injection schedule (two 105 mg subcutaneous injections monthly, for a total dose of 210 mg) should not be extended. After the 12-month course, transition to an anti-resorptive agent (denosumab or a bisphosphonate) is mandatory to maintain bone density gains [11]. Opioid management continues independently of this transition.

For patients on tramadol specifically, warn about the seizure risk at doses exceeding 400 mg per day and the additive risk with other serotonergic medications (SSRIs, SNRIs, triptans). A seizure-related fall during romosozumab therapy could negate the skeletal benefits of treatment entirely.

Dose Adjustment Guidance

No dose adjustment is required for either romosozumab or any opioid based on co-administration. Romosozumab is dosed at a fixed 210 mg subcutaneously once monthly regardless of body weight, renal function, or concomitant medications. Opioid dosing follows standard titration principles based on pain severity, patient response, and tolerability.

The Endocrine Society's 2020 guidelines on osteoporosis pharmacotherapy do not list opioids as agents requiring adjustment during romosozumab therapy [13]. The American Geriatrics Society Beers Criteria (2023 update) recommends avoiding opioids in older adults when possible, but this recommendation is independent of romosozumab use and reflects general fall-risk and adverse-event concerns in the geriatric population [14].

If a patient's pain worsens during the romosozumab treatment course, investigate new fractures (romosozumab reduces but does not eliminate fracture risk) or other pain etiologies before escalating opioid doses. Bone scintigraphy or MRI with STIR sequences can differentiate new fractures from degenerative pain.

When to Involve Specialist Consultation

Most patients receiving romosozumab and opioids concurrently can be managed in primary care or by an endocrinologist with standard monitoring. Specialist referral is appropriate in the following scenarios: patients with a history of cardiovascular events within the past 24 months (cardiology review before romosozumab initiation), patients on high-dose opioid therapy (morphine milligram equivalents exceeding 90 MME per day, per CDC guideline thresholds), patients with CYP2D6 poor or ultra-rapid metabolizer status (pharmacogenomic consult for opioid selection), and patients with recurrent falls despite intervention (geriatric medicine or physiatry referral for comprehensive fall-risk reduction) [12].

The combination of romosozumab and opioids does not constitute a contraindication. Prescribers should document the clinical rationale for concurrent use, confirm baseline cardiovascular risk is acceptable, and implement structured fall-prevention counseling at every monthly romosozumab visit.

Baseline P1NP measurement before the first romosozumab injection provides the most reliable reference point for tracking anabolic response during the 12-month treatment window [6].